Pandion is focused on developing therapeutics for a wide range of autoimmune and inflammatory indications.
We are rapidly advancing our lead program, an IL-2 mutein fusion protein that preferentially expands T regulatory cells, to the clinic while supporting a robust pipeline of systemic immune modulators and targeted therapeutics focused on the gut, liver, skin, kidneys, and pancreas.
Primary indications for current programs include:
- Inflammatory bowel disease
- Autoimmune liver diseases
- Autoimmune skin conditions
- Various kidney indications
- Type 1 diabetes